• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

77
12
10
10
5

COUNTRY

11
4
1
1

PRICE

496
498
500
550

PUBLISHED

0
0
3
550

PRODUCT TYPE

482
67
1

Prostate Cancer

The second leading cause of new cancer cases in men worldwide with over two million sufferers in the US alone, prostate cancer is typically a disease that affects older men and is thus on the increase as global life expectancies continue to rise. It is also one of the largest sectors of the pharmaceutical oncology industry. Expertly formulated reports in this section will help you to formulate effective market strategies by answering key questions such as who are the main and key niche players, what are the new drugs and therapies (including vaccines and therapeutic antibodies) in the pipeline, and what are the latest areas of pharmaceutical R&D. Manufacturers will find multiple report options to assist them in assessing competition and market opportunities. Show Less Read more

PRODUCT TITLE

Prostate Cancer Treatment Drugs Markets in China

China's demand for Prostate Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's...

June 2014
FROM
Analytical Tool - Prostate Cancer Analytical Tool - Prostate Cancer - Product Thumbnail Image

Analytical Tool - Prostate Cancer

"Analytical Tool - Prostate Cancer" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in prostate cancer R&D and business development. It is at the same...

March 2014

US Prostate Cancer Drug Pipeline Analysis

Prostate cancer has emerged as one of the most commonly diagnosed cancer among men in the US According to the American Cancer Society, there were close to 242,000 new cases of prostate cancer in the...

October 2013
FROM
Triple Analysis: Colorectal Cancer, Melanoma and Prostate Cancer Triple Analysis: Colorectal Cancer, Melanoma and Prostate Cancer - Product Thumbnail Image

Triple Analysis: Colorectal Cancer, Melanoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Triple Analysis: Lung Cancer, Melanoma and Prostate Cancer Triple Analysis: Lung Cancer, Melanoma and Prostate Cancer - Product Thumbnail Image

Triple Analysis: Lung Cancer, Melanoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Triple Analysis: Melanoma, Prostate Cancer and Protein Kinase Inhibitors Triple Analysis: Melanoma, Prostate Cancer and Protein Kinase Inhibitors - Product Thumbnail Image

Triple Analysis: Melanoma, Prostate Cancer and Protein Kinase Inhibitors

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual...

June 2013
FROM
Triple Analysis: Melanoma, Prostate Cancer and Antibodies Triple Analysis: Melanoma, Prostate Cancer and Antibodies - Product Thumbnail Image

Triple Analysis: Melanoma, Prostate Cancer and Antibodies

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated...

June 2013
FROM
Triple Analysis: Melanoma, Pancreatic Cancer and Prostate Cancer Triple Analysis: Melanoma, Pancreatic Cancer and Prostate Cancer - Product Thumbnail Image

Triple Analysis: Melanoma, Pancreatic Cancer and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Melanoma, Pancreatic Cancer and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Triple Analysis: Melanoma, Prostate Cancer and Apoptosis Triple Analysis: Melanoma, Prostate Cancer and Apoptosis - Product Thumbnail Image

Triple Analysis: Melanoma, Prostate Cancer and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated...

June 2013
FROM
Triple Analysis: Leukemia, Melanoma and Prostate Cancer Triple Analysis: Leukemia, Melanoma and Prostate Cancer - Product Thumbnail Image

Triple Analysis: Leukemia, Melanoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Leukemia, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria in...

June 2013
FROM
Triple Analysis: Melanoma, Prostate Cancer and Angiogenesis Triple Analysis: Melanoma, Prostate Cancer and Angiogenesis - Product Thumbnail Image

Triple Analysis: Melanoma, Prostate Cancer and Angiogenesis

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated...

June 2013
FROM

KOL Insight: Prostate Cancer: Competition Intensifies in Race to the Top

The Prostate Cancer market has seen a number of progressive changes in recent years The launches of Johnson & Johnson's Zytiga (abiraterone acetate) and Medivation/Astellas's Xtandi (enzalutamide) has...

June 2013
FROM
Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top - Product Thumbnail Image

Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top

Charting the Future Prostate Cancer Market Landscape The prostate cancer market has experienced substantial changes in the last five years with patent expiries of key compounds and approvals of new...

June 2013
FROM
Global Prostate Cancer Pipeline Capsule - 2013 Global Prostate Cancer Pipeline Capsule - 2013 - Product Thumbnail Image

Global Prostate Cancer Pipeline Capsule - 2013

Fore Pharma's latest report ‘Global Prostate Cancer Pipeline Capsule – 2013' provides up-to-date information on key Research and Development (R&D) activities in the global prostate cancer market It...

April 2013
FROM
Triple Analysis: Prostate Cancer, Apoptosis and Peptides Triple Analysis: Prostate Cancer, Apoptosis and Peptides - Product Thumbnail Image

Triple Analysis: Prostate Cancer, Apoptosis and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides)....

January 2013
FROM
Boston Scientific Corp,(BSX) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages Boston Scientific Corp,(BSX) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages - Product Thumbnail Image

Boston Scientific Corp,(BSX) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages

Why You Should Buy This Report: A value-packed package of corporate financial analysis, for Boston Scientific Corp (BSX), plus vital industry benchmarks and extensive operating ratios, along with an...

December 2012
FROM
BSML, Inc.,(BSMLQ) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages BSML, Inc.,(BSMLQ) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages - Product Thumbnail Image

BSML, Inc.,(BSMLQ) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages

Why You Should Buy This Report: A value-packed package of corporate financial analysis, for BSML, Inc. (BSMLQ), plus vital industry benchmarks and extensive operating ratios, along with an analysis...

December 2012
FROM
SRI/Surgical Express Inc,(Subsidiary) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages SRI/Surgical Express Inc,(Subsidiary) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages - Product Thumbnail Image

SRI/Surgical Express Inc,(Subsidiary) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages

Why You Should Buy This Report: A value-packed package of corporate financial analysis, for SRI/Surgical Express Inc (Subsidiary), plus vital industry benchmarks and extensive operating ratios, along...

December 2012
FROM
Stereotaxis, Inc.,(STXS) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages Stereotaxis, Inc.,(STXS) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages - Product Thumbnail Image

Stereotaxis, Inc.,(STXS) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages

Why You Should Buy This Report: A value-packed package of corporate financial analysis, for Stereotaxis, Inc. (STXS), plus vital industry benchmarks and extensive operating ratios, along with an analysis...

December 2012
FROM
Sunrise Senior Living,(SRZ) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages Sunrise Senior Living,(SRZ) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages - Product Thumbnail Image

Sunrise Senior Living,(SRZ) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages

Why You Should Buy This Report: A value-packed package of corporate financial analysis, for Sunrise Senior Living (SRZ), plus vital industry benchmarks and extensive operating ratios, along with an...

December 2012
FROM
Loading Indicator

Our Clients

Our clients' logos